Diabetic Hemodialysis. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group1: The zinc-supplementation group(n=20) will receive a 220-mg Zinc sulfate capsule (containing 50 mg zinc) manufactured by Alhavi Pharmaceutical Company (Tehran, Iran
for 56 days. Intervention 2: Control group:The control-group(n=20) will receive a placebo capsule(220-mg corn starch), for 56 days.
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Diabetic Hemodialysis patients Age:15-70 years old Pass at least 6 months from hemodialysis Not having inflammatory diseases affecting on serum inflammatory markers Not consuming supplements containing antioxidants, Zinc supplement, vitamins E and C supplements and Steroidal and Non-Steroidal Anti-Inflammatory drugs(NSAIDs) one month before the start of the study
Exclusion criteria
Exclusion criteria: Consumption of antibiotics or existence of infectious and feverish illnesses one month before starting the study Existence of diseases affecting serum galectin-3 such as cardiovascular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum galectin-3. Timepoint: Before and after 8-week intervention. Method of measurement: It measured by ELISA method with standard kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr mansour karajibani
Zahedan University of Medical Sciences
Outcome results
None listed